Prohibitin-1 deficiency promotes inflammation and increases sensitivity to liver injury

Journal of Proteomics

Volumn 75, Issue 18, 2012, Pages 5783-5792

  Sánchez Quiles, Virginia ^a   Segura, Víctor ^a   Bigaud, Emilie ^a   He, Bin ^b   O'Malley, Bert W ^b   Santamaría, Enrique ^a   Prieto, Jesús ^a   Corrales, Fernando J ^a  

^a UNIVERSITY OF NAVARRA   (Spain)

^b BAYLOR COLLEGE OF MEDICINE   (United States)

Author keywords

Inflammation; Liver injury; Prohibitin 1; Proteomics

Indexed keywords

ADENYLATE KINASE; CHOLINE; CYTOKINE; METHIONINE; PROHIBITIN; PROHIBITIN 1; PROTEIN KINASE B; PROTEIN TYROSINE PHOSPHATASE SHP 1; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DISORDERS OF MITOCHONDRIAL FUNCTIONS; GENE EXPRESSION; INFLAMMATION; LIVER CELL DAMAGE; LIVER INJURY; LYMPHOCYTE; MALE; MORTALITY; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN DEFICIENCY; PROTEOMICS; SPLEEN CELL; TRANSCRIPTOMICS;

ANIMALS; CHOLINE DEFICIENCY; FATTY LIVER; INFLAMMATION; MALE; METHIONINE; MICE; REPRESSOR PROTEINS; TRANSCRIPTOME;

MUS;

EID: 84866183373     PISSN: 18743919     EISSN: 18767737     Source Type: Journal    
DOI: 10.1016/j.jprot.2012.08.009     Document Type: Article

References (53)

1. Williams R. Global challenges in liver disease. Hepatology 2006, 44:521-526.
2. Bataller R., Brenner D.A. Liver fibrosis. J Clin Invest 2005, 115:209-218.
3. Serviddio G., Bellanti F., Sastre J., Vendemiale G., Altomare E. Targeting mitochondria: a new promising approach for the treatment of liver diseases. Curr Med Chem 2010, 17:2325-2337.
4. Mishra S., Murphy L.C., Murphy L.J. The Prohibitins: emerging roles in diverse functions. J Cell Mol Med 2006, 10:353-363.
5. Merkwirth C., Langer T. Prohibitin function within mitochondria: essential roles for cell proliferation and cristae morphogenesis. Biochim Biophys Acta 2009, 1793:27-32.
6. Mishra S., Ande S.R., Nyomba B.L. The role of prohibitin in cell signaling. FEBS J 2010, 277:3937-3946.
7. Fusaro G., Dasgupta P., Rastogi S., Joshi B., Chellappan S. Prohibitin induces the transcriptional activity of p53 and is exported from the nucleus upon apoptotic signaling. J Biol Chem 2003, 278:47853-47861.
8. Kang X., Zhang L., Sun J., Ni Z., Ma Y., Chen X., et al. Prohibitin: a potential biomarker for tissue-based detection of gastric cancer. J Gastroenterol 2008, 43:618-625.
9. Liu T., Tang H., Lang Y., Liu M., Li X. MicroRNA-27a functions as an oncogene in gastric adenocarcinoma by targeting prohibitin. Cancer Lett 2009, 273:233-242.
10. Xu D.H., Tang J., Li Q.F., Shi S.L., Chen X.F., Liang Y. Positional and expressive alteration of prohibitin during the induced differentiation of human hepatocarcinoma SMMC-7721 cells. World J Gastroenterol 2008, 14:5008-5014.
11. Theiss A.L., Idell R.D., Srinivasan S., Klapproth J.M., Jones D.P., Merlin D., et al. Prohibitin protects against oxidative stress in intestinal epithelial cells. FASEB J 2007, 21:197-206.
12. Theiss A.L., Vijay-Kumar M., Obertone T.S., Jones D.P., Hansen J.M., Gewirtz A.T., et al. Prohibitin is a novel regulator of antioxidant response that attenuates colonic inflammation in mice. Gastroenterology 2009, 137(199-208):e1-e6. 208.
13. Gregory-Bass R.C., Olatinwo M., Xu W., Matthews R., Stiles J.K., Thomas K., et al. Prohibitin silencing reverses stabilization of mitochondrial integrity and chemoresistance in ovarian cancer cells by increasing their sensitivity to apoptosis. Int J Cancer 2008, 122:1923-1930.
14. Mishra S., Murphy L.C., Nyomba B.L., Murphy L.J. Prohibitin: a potential target for new therapeutics. Trends Mol Med 2005, 11:192-197.
15. Theiss A.L., Sitaraman S.V. The role and therapeutic potential of prohibitin in disease. Biochim Biophys Acta 2011, 1813:1137-1143.
16. Santamaria E., Avila M.A., Latasa M.U., Rubio A., Martín-Duce A., Lu S.C., et al. Functional proteomics of nonalcoholic steatohepatitis: mitochondrial proteins as targets of S-adenosylmethionine. Proc Natl Acad Sci U S A 2003, 100:3065-3070.
17. Garcia-Ruiz I., Fernandez-Moreira D., Solis-Munoz P., Rodriguez-Juan C., Diaz-Sanjuan T., Munoz-Yague T., et al. Mitochondrial complex I subunits are decreased in murine nonalcoholic fatty liver disease: implication of peroxynitrite. J Proteome Res 2010, 9:2450-2459.
18. Bailey S.M., Robinson G., Pinner A., Chamlee L., Ulasova E., Pompilius M., et al. S-adenosylmethionine prevents chronic alcohol-induced mitochondrial dysfunction in the rat liver. Am J Physiol Gastrointest Liver Physiol 2006, 291:G857-G867.
19. Tomita K., Tamiya G., Ando S., Ohsumi K., Chiyo T., Mizutani A., et al. Tumour necrosis factor alpha signalling through activation of Kupffer cells plays an essential role in liver fibrosis of non-alcoholic steatohepatitis in mice. Gut 2006, 55:415-424.
20. Sun Q., Miao M., Jia X., Guo W., Wang L., Yao Z., et al. Subproteomic analysis of the mitochondrial proteins in rats 24h after partial hepatectomy. J Cell Biochem 2008, 105:176-184.
21. Ko K.S., Tomasi M.L., Iglesias-Ara A., French B.A., French S.W., Ramani K., et al. Liver-specific deletion of prohibitin 1 results in spontaneous liver injury, fibrosis, and hepatocellular carcinoma in mice. Hepatology 2010, 52:2096-2108.
22. He B., Feng Q., Mukherjee A., Lonard D.M., DeMayo F.J., Katzenellenbogen B.S., et al. A repressive role for prohibitin in estrogen signaling. Mol Endocrinol 2008, 22:344-360.
23. Schröder P.C., Segura V., Riezu J.I., Sangro B., Mato J.M., Prieto J., et al. A signature of six genes highlights defects on cell growth and specific metabolic pathways in murine and human hepatocellular carcinoma. Funct Integr Genomics 2011, 11:419-429.
24. Sánchez-Quiles V., Santamaria E., Segura V., Sesma L., Prieto J., Corrales F.J. Prohibitin deficiency blocks proliferation and induces apoptosis in human hepatoma cells: molecular mechanisms and functional implications. Proteomics 2010, 10:1609-1620.
25. Sánchez-Quiles V., Mora M.I., Segura V., Greco A., Epstein A.L., Foschini M.G., et al. HSV-1 Cgal+ infection promotes quaking RNA binding protein production and induces nuclear-cytoplasmic shuttling of quaking I-5 isoform in human hepatoma cells. Mol Cell Proteomics 2011, 10. M111.009126.
26. Toogood H.S., Leys D., Scrutton N.S. Dynamics driving function: new insights from electron transferring flavoproteins and partner complexes. FEBS J 2007, 274:5481-5504.
27. Eismann T., Huber N., Shin T., Kuboki S., Galloway E., Wyder M., et al. Peroxiredoxin-6 protects against mitochondrial dysfunction and liver injury during ischemia-reperfusion in mice. Am J Physiol Gastrointest Liver Physiol 2009, 296:G266-G274.
28. Moon K.H., Lee Y.M., Song B.J. Inhibition of hepatic mitochondrial aldehyde dehydrogenase by carbon tetrachloride through JNK-mediated phosphorylation. Free Radic Biol Med 2010, 48:391-398.
29. Kammoun H.L., Chabanon H., Hainault I., Luquet S., Magnan C., Koike T., et al. GRP78 expression inhibits insulin and ER stress-induced SREBP-1c activation and reduces hepatic steatosis in mice. J Clin Invest 2009, 119:1201-1215.
30. Viollet B., Foretz M., Guigas B., Horman S., Dentin R., Bertrand L., et al. Activation of AMP-activated protein kinase in the liver: a new strategy for the management of metabolic hepatic disorders. J Physiol 2006, 574:41-53.
31. Shaw R.J., Kosmatka M., Bardeesy N., Hurley R.L., Witters L.A., DePinho R.A., et al. The tumor suppressor LKB1 kinase directly activates AMP-activated kinase and regulates apoptosis in response to energy stress. Proc Natl Acad Sci U S A 2004, 101:3329-3335.
32. Gil-Guerrero L., Dotor J., Huibregtse I.L., Casares N., López-Vázquez A.B., Rudilla F., et al. In vitro and in vivo down-regulation of regulatory T cell activity with a peptide inhibitor of TGF-beta1. J Immunol 2008, 181:126-135.
33. Rizki G., Arnaboldi L., Gabrielli B., Yan J., Lee G.S., Ng R.K., et al. Mice fed a lipogenic methionine-choline-deficient diet develop hypermetabolism coincident with hepatic suppression of SCD-1. J Lipid Res 2006, 47:2280-2290.
34. Suhir H., Etzioni A. The role of Toll-like receptor signaling in human immunodeficiencies. Clin Rev Allergy Immunol 2010, 38:11-19.
35. Testro A.G., Visvanathan K. Toll-like receptors and their role in gastrointestinal disease. J Gastroenterol Hepatol 2009, 24:943-954.
36. Hammer M., Echtenachter B., Weighardt H., Jozefowski K., Rose-John S., Mannel D.N., et al. Increased inflammation and lethality of Dusp1-/- mice in polymicrobial peritonitis models. Immunology 2010, 131:395-404.
37. Salojin K.V., Owusu I.B., Millerchip K.A., Potter M., Platt K.A., Oravecz T. Essential role of MAPK phosphatase-1 in the negative control of innate immune responses. J Immunol 2006, 176:1899-1907.
38. Todoroki H., Nakamura S., Higure A., Okamoto K., Takeda S., Nagata N., et al. Neutrophils express tissue factor in a monkey model of sepsis. Surgery 2000, 127:209-216.
39. Wunder C., Scott J.R., Lush C.W., Brock R.W., Bihari A., Harris K., et al. Heme oxygenase modulates hepatic leukocyte sequestration via changes in sinusoidal tone in systemic inflammation in mice. Microvasc Res 2004, 68:20-29.
40. Mookherjee N., Brown K.L., Bowdish D.M., Doria S., Falsafi R., Hokamp K., et al. Modulation of the TLR-mediated inflammatory response by the endogenous human host defense peptide LL-37. J Immunol 2006, 176:2455-2464.
41. Fernandez-Botran R. Soluble cytokine receptors: novel immunotherapeutic agents. Expert Opin Investig Drugs 2000, 9:497-514.
42. Vieira S.M., Lemos H.P., Grespan R., Napimoga M.H., Dal-Secco D., Freitas A., et al. A crucial role for TNF-alpha in mediating neutrophil influx induced by endogenously generated or exogenous chemokines, KC/CXCL1 and LIX/CXCL5. Br J Pharmacol 2009, 158:779-789.
43. Matheny H.E., Deem T.L., Cook-Mills J.M. Lymphocyte migration through monolayers of endothelial cell lines involves VCAM-1 signaling via endothelial cell NADPH oxidase. J Immunol 2000, 164:6550-6559.
44. Wolpe S.D., Cerami A. Macrophage inflammatory proteins 1 and 2: members of a novel superfamily of cytokines. FASEB J 1989, 3:2565-2573.
45. Zeremski M., Petrovic L.M., Talal A.H. The role of chemokines as inflammatory mediators in chronic hepatitis C virus infection. J Viral Hepat 2007, 14:675-687.
46. Matsumoto M., Seya T. TLR3: interferon induction by double-stranded RNA including poly(I:C). Adv Drug Deliv Rev 2008, 60:805-812.
47. Ande S.R., Gu Y., Nyomba B.L., Mishra S. Insulin induced phosphorylation of prohibitin at tyrosine 114 recruits Shp1. Biochim Biophys Acta 2009, 1793:1372-1378.
48. Zhang J., Somani A.K., Siminovitch K.A. Roles of the SHP-1 tyrosine phosphatase in the negative regulation of cell signalling. Semin Immunol 2000, 12:361-378.
49. Stefanova I., Hemmer B., Vergelli M., Martin R., Biddison W.E., Germain R.N. TCR ligand discrimination is enforced by competing ERK positive and SHP-1 negative feedback pathways. Nat Immunol 2003, 4:248-254.
50. Junttila M.R., Li S.P., Westermarck J. Phosphatase-mediated crosstalk between MAPK signaling pathways in the regulation of cell survival. FASEB J 2007, 22:954-965.
51. Samanta A.K., Chakraborty S.N., Wang Y., Kantarjian H., Sun X., Hood J., et al. Jak2 inhibition deactivates Lyn kinase through the SET-PP2A-SHP1 pathway, causing apoptosis in drug-resistant cells from chronic myelogenous leukemia patients. Oncogene 2009, 28:1669-1681.
52. Beurel E., Michalek S.M., Jope R.S. Innate and adaptive immune responses regulated by glycogen synthase kinase-3 (GSK3). Trends Immunol 2010, 31:24-31.
53. Chiu C.F., Ho M.Y., Peng J.M., Hung S.W., Lee W.H., Liang C.M., et al. Raf activation by Ras and promotion of cellular metastasis require phosphorylation of prohibitin in the raft domain of the plasma membrane. Oncogene 2012, 1-11. 10.1038/onc.2012.86.